Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis

Background: Scalp involvement in plaque psoriasis is challenging to treat. Objective: To evaluate the efficacy and safety of deucravacitinib (DEUC) in scalp psoriasis. Methods: POETYK PSO-1 and PSO-2 were global phase 3, 52 -week, double -blinded trials in adults with moderate to severe psoriasis. Patients were randomized 1:2:1 to oral placebo, DEUC 6 mg once daily, or apremilast 30 mg twice daily. This pooled secondary analysis evaluated scalp -specific Physician Global Assessment score of 0 or 1 (0/1), >= 90% improvement from baseline in Psoriasis Scalp Severity Index, and change from baseline in Psoriasis Scalp Severity Index. Adverse events were evaluated through week 16. Results: Overall, 1084 patients with moderate to severe scalp psoriasis at baseline were included. At week 16, response rates were greater with DEUC versus placebo or apremilast for scalp -specific Physician Global Assessment 0/1 (64.0% vs 17.3% vs 37.7%; P < .0001), >= 90% improvement from baseline in Psoriasis Scalp Severity Index (50.6% vs 10.5% vs 26.1%; P < .0001), and change from baseline in Psoriasis Scalp Severity Index. Responses were maintained through 52 weeks with continuous DEUC. Safety was consistent with the entire study population. Limitations: Lack of data in milder scalp psoriasis. Conclusion: DEUC was significantly more efficacious than placebo or apremilast in improving moderate to severe scalp psoriasis and was well tolerated.